Sale!

PMLRARA Quantitative Single Form Test Cost

Original price was: 1,690 د.إ.Current price is: 1,520 د.إ.

-10%

The PML/RARA Quantitative Single Form Test is a specialized diagnostic assay utilized for the detection and quantification of the PML/RARA fusion gene, which is primarily associated with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). This test plays a crucial role in the diagnosis, prognosis, and monitoring of treatment response in patients with APL. Utilizing advanced molecular techniques, the test accurately measures the levels of the PML/RARA transcript in blood or bone marrow samples, providing essential information for personalized patient management.

Conducted at DNA Labs UAE, a state-of-the-art facility known for its comprehensive range of genetic and molecular diagnostic services, the PML/RARA Quantitative Single Form Test is performed under stringent quality control measures to ensure accuracy and reliability. The cost of the test is set at 1520 AED, reflecting the sophisticated nature of the technology and expertise involved in conducting the assay. For patients and healthcare providers, this test represents a critical tool in the effective management of acute promyelocytic leukemia, offering insights that guide treatment decisions and contribute to improved outcomes.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

PMLRARA Quantitative Single form Test

At DNA Labs UAE, we offer the PMLRARA Quantitative Single form Test for AED 1520.0. This test measures the amount of PMLRARA fusion gene in a patient’s blood or bone marrow sample.

Test Details

The PMLRARA quantitative test is used to diagnose acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). It measures the fusion gene formed by the PML and RARA genes. This fusion gene is crucial in the development of APL and serves as a diagnostic marker for the disease.

The test is performed using real-time polymerase chain reaction (PCR), which amplifies and quantifies the amount of PMLRARA fusion gene present in the sample. The results are reported as a numerical value, indicating the level of PMLRARA in the patient’s blood or bone marrow.

Symptoms and Diagnosis

Patients with APL may experience symptoms such as easy bruising, bleeding, fatigue, and frequent infections. A diagnosis of APL is typically made through a combination of physical examinations, blood tests, and bone marrow biopsies.

Referring Details

To undergo the PMLRARA Quantitative Single form Test, a doctor’s prescription is required. However, prescriptions are not applicable for surgery and pregnancy cases or individuals planning to travel abroad.

Report Delivery

After the test, the report will be delivered within 2-3 days.

Test Department

This test falls under the genetics department at DNA Labs UAE.

Pre Test Information

PMLRARA Quantitative Single form Test can be done with a doctor’s prescription. However, it is not applicable for surgery and pregnancy cases or individuals planning to travel abroad.

Conclusion

The PMLRARA Quantitative Single form Test is an essential tool in the management of APL patients. It helps guide treatment decisions and monitor disease progression, allowing healthcare providers to tailor treatment plans and optimize outcomes.

Test Name PMLRARA Quantitative Single form Test
Components EDTA Vacutainer (4ml)
Price 1520.0 AED
Sample Condition Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery 2-3 days
Method Real Time PCR
Test type Genetics
Doctor General Physician
Test Department:
Pre Test Information PML/RARA Quantitative Single form] can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

PML/RARA quantitative refers to a laboratory test that measures the amount of PML/RARA fusion gene in a patient’s blood or bone marrow sample. PML/RARA is a genetic abnormality commonly found in patients with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML).

The PML/RARA fusion gene is formed when parts of two separate genes, PML and RARA, fuse together. This fusion gene plays a crucial role in the development of APL and is used as a diagnostic marker for this disease.

The quantitative measurement of PML/RARA is important for monitoring the response to treatment and assessing the risk of relapse in APL patients. A decrease in the level of PML/RARA during treatment indicates a good response, while an increase or persistence of the fusion gene suggests a higher risk of relapse.

The test is typically performed using a technique called real-time polymerase chain reaction (PCR), which amplifies and quantifies the amount of PML/RARA fusion gene present in the sample. The results are reported as a numerical value, representing the level of PML/RARA in the patient’s blood or bone marrow.

The PML/RARA quantitative test is an important tool in the management of APL patients, as it helps guide treatment decisions and monitor disease progression. It allows healthcare providers to tailor treatment plans to individual patients and optimize their outcomes.